SLC5A2 and bacterial urinary tract infection: The overall incidence rate of UTI in the SGLT2 inhibitor group was 33.49%, divided into 34.00% for dapagliflozin and 33.03% for empagliflozin, respectively, whereas the incidence rate of UTI in the non-SGLT2 inhibitor group was 11.72% (Figure 1).